查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
癌症微生物群基因體測序市場 - 2017-2027年全球行業規模、佔有率、趨勢、機會及預測 按組分、按技術、按應用、按最終用戶、按公司和按地區分類
市場調查報告書
商品編碼
1303137

癌症微生物群基因體測序市場 - 2017-2027年全球行業規模、佔有率、趨勢、機會及預測 按組分、按技術、按應用、按最終用戶、按公司和按地區分類

Cancer Microbiome Sequencing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Component, By Technology, By Application, By End User, By company and By Region
出版日期: | 出版商: TechSci Research | 英文 116 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球癌症微生物群基因體測序市場預計將在2023-2027年的預測期間觀察到令人印象深刻的成長。主要因素，包括癌症發生率的成長和越來越重視微生物群基因體在癌症領域的潛力，推動市場的成長。微生物群基因體是生長或存在於環境中的微生物群落，如唾液、皮膚層、人體的口腔粘膜和胃腸道。微生物群基因體測序是一種有價值的工具，用於研究和分析位於人體內部或外部的微生物群體，以便更佳了解人類的微生物。微生物群基因體研究的主要目的是了解微生物在人類健康和疾病中的作用和功能。促進市場成長的其他因素有：測序成本的降低、研發活動的增加、全球癌症病例數量的指數上升、臨床試驗數量的增加、基於微生物群基因體的新型診斷工具開發的增加以支援醫生的工作、生物技術公司的投資增加、用於疾病診斷和早期檢測的微生物群基因體測序服務需求的增加，世界人口的增加，對使用微生物群基因體測序技術的認知不斷提高，醫療保健支出的增加，研究人員對了解微生物群基因體在人類健康和疾病中的作用的興趣增加，以及新興子市場的巨大潛力。

癌症發病率的上升促進市場成長。

肺癌、宮頸癌、乳腺癌、皮膚癌、咽喉癌等癌症的發病率不斷上升，促進了市場的成長。根據世衛組織的資料，2020年，癌症是全世界的主要死因，報告的死亡人數約為1000萬，或大約六分之一的死亡。最常見的癌症是肺癌、結腸和直腸癌、前列腺癌和乳腺癌。由於飲酒、吸煙、不健康的飲食選擇和久坐不動的生活方式，患癌症的病例數量激增。因此，對癌症微生物群基因體測序的需求上升，這又促進了市場的成長。按照世衛組織的說法，許多癌症如果在早期階段被發現，就可以得到有效治療。

研究人員對微生物群基因體的潛力越來越重視，生物技術公司的支援也在增加。

對微生物群基因體診斷和預防各種癌症的潛力的日益重視推動市場的成長。各種研究人員學習和研究微生物群基因體在癌症領域的潛力。研究人員得到生物技術公司的支援，以揭示與微生物群基因體對癌症進展和表現的影響有關的見解。此外，癌症微生物群基因體測序服務和產品的發展幫助研究界制定了有效的戰略，以發現與微生物群基因體相關的新型癌症生物標記，這些標誌物可用於開發癌症微生物群基因體測序產品，供臨床使用。

可用的客製化服務

利用給定的市場資料，TechSci Research根據公司的具體需要提供客製化服務。本報告有以下客製化選項：

公司資訊

  • 其他市場參與者（最多5家）的詳細分析和概況。

目錄

第一章：產品概述

第二章：研究方法

第三章：執行摘要

第四章：COVID-19對全球癌症微生物群基因體測序市場的影響

第五章：客戶的聲音

第六章：全球癌症微生物群基因體測序的市場前景

  • 市場規模和預測
    • 按價值
  • 市場佔有率與預測
    • 按組件（試劑盒和檢測方法、軟體、服務）分類
    • 按技術分類（下一代測序 v/s 聚合酶鏈反應）
    • 按應用（轉化研究 v/s 臨床診斷）分類
    • 按終端用戶（生物技術和製藥公司，學術和研究機構，醫院和診所，其他）
    • 按公司分類(2021年)
    • 按地區分類
  • 市場地圖

第七章：北美癌症微生物群基因體測序市場前景

  • 市場規模和預測
    • 按價值
  • 市場佔有率與預測
    • 按組件分類
    • 按技術分類
    • 按應用分類
    • 按終端用戶
    • 按國家分類
  • 北美洲：國家分析
    • 美國
    • 美國
    • 墨西哥

第8章：歐洲癌症微生物群基因體測序市場前景

  • 市場規模和預測
    • 按價值
  • 市場佔有率與預測
    • 按成分分類
    • 按技術分類
    • 按應用分類
    • 按終端用戶
    • 按國家分類
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第九章：亞太地區癌症微生物群基因體測序市場前景

  • 市場規模和預測
    • 按價值
  • 市場佔有率與預測
    • 按成分分類
    • 按技術分類
    • 按應用分類
    • 按終端用戶
    • 按國家分類
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第十章：南美癌症微生物群基因體測序市場前景

  • 市場規模和預測
    • 按價值
  • 市場佔有率與預測
    • 按成分分類
    • 按技術分類
    • 按應用分類
    • 按終端用戶
    • 按國家分類
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第11章：中東和非洲癌症微生物群基因體測序的市場前景

  • 市場規模和預測
    • 按價值
  • 市場佔有率與預測
    • 按組件分類
    • 按技術分類
    • 按應用分類
    • 按終端用戶
    • 按國家分類
  • MEA: 國家分析
    • 南非癌症微生物群基因體測序
    • 沙烏地阿拉伯癌症微生物群基因體測序
    • 阿拉伯聯合大公國癌症微生物群基因體測序
    • 土耳其癌症微生物群基因體測序
    • 埃及癌症微生物群基因體測序

第十二章：市場動態

  • 驅動力
  • 挑戰

第十三章：市場趨勢與發展

第十四章：競爭格局

  • Illumina, Inc.
  • Eurofins Scientific SE
  • QIAGEN NV
  • Thermo Fischer Scientific, Inc.
  • Oxford Nanopore Technologies plc.
  • OraSure Technologies, Inc.
  • Pacific Biosciences of California, Inc.
  • Psomagen, Inc
  • Prescient Medicine Holdings, Inc.
  • Micronoma Inc.

第十五章：戰略建議

簡介目錄
Product Code: 14153

The global cancer microbiome sequencing market is anticipated to observe impressive growth during the forecast period 2023-2027. The major factors, including growing occurrences of cancer and increasing emphasis on the microbiome's potential in the field of cancer, are fueling the growth of the market. Microbiomes are the community of microorganisms that grow or exist in an environment, such as saliva, skin layers, oral mucosa of the human body, and the gastrointestinal tract. Microbiome sequencing is a valuable tool that is used to study and analyze the microbes groups located in or out of the human body to have a better understanding of human microbes. The main aim of a microbiome research study is to understand the role and function of microbes in human health and disease. The other factors supporting the market's growth are decreasing cost of sequencing, the rise in R&D activities, the exponential rise in the number of cancer cases worldwide, the increasing number of clinical trials, the rise in the development of novel diagnostic tools based on the microbiome for supporting physicians, increasing investments by biotechnology companies, rise in demand for microbiome sequencing services for diagnosis and early detection of the diseases, rise in world population, growing awareness of the use of microbiome sequencing technology, rise in the healthcare expenditure, rising interest of researchers in understanding the role of the microbiome in human health and disease, and immense potential for emerging submarkets.

The rising Prevalence of Cancer supports Market Growth.

Growing incidences of cancer, such as lung, cervical, breast, skin, throat, and others, are augmenting the growth of the market. According to WHO, in 2020, cancer is a major cause of death across the world, reporting approximately 10 million deaths, or about one in six deaths. The most common cancers are lung, colon and rectum, prostate cancers, and breast. There is a surge in the number of cases suffering from cancer caused due to consumption of alcohol, tobacco use, unhealthy eating choices, and sedentary lifestyle. Therefore, the need for cancer microbiome sequencing is rising, which in turn, bolsters the growth of the market. As per WHO, many cancers can be treated effectively if detected in an early stage.

Increasing Emphasis by Researchers on the Microbiome's Potential and Rising Support from Biotechnology Companies.

The rising focus on the microbiome's potential to diagnose and prevent various cancers is fueling the growth of the market. Various researchers are studying and researching the microbiome's potential in the field of cancers. Researchers are being supported by biotech companies to unravel insights pertaining to the microbiome's influence on cancer progression and manifestation. Furthermore, the development of cancer microbiome sequencing services and products has aided the research community in creating effective strategies for discovering novel cancer biomarkers allied with the microbiome, which could be used for the development of cancer microbiome sequencing products for clinical use.

Market Segmentation

The global cancer microbiome sequencing market is segmented into components, technology, application, end-user, and company. Based on components, the market is divided into kits & assays, software, and services. Based on technology, the market is divided into next-generation sequencing and polymerase chain reaction. Based on application, the market is divided into translational research and clinical diagnostics. Based on end-user, the market is divided into biotechnology & pharmaceutical companies, academic & research institutions, hospitals & clinics, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising incidences of cancer and a rise in R&D activities in the country.

Market Players

Illumina, Inc., Eurofins Scientific SE, QIAGEN NV, Thermo Fischer Scientific, Inc., Oxford Nanopore Technologies plc., OraSure Technologies, Inc., Pacific Biosciences of California, Inc., Psomagen, Inc, Prescient Medicine Holdings, Inc., and Micronoma Inc. are some of the leading companies operating in the market.

Report Scope

In this report, global cancer microbiome sequencing market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Cancer Microbiome Sequencing Market, By component:

  • Kits & Assays
  • software
  • Services

Cancer Microbiome Sequencing Market, By technology:

  • Next-Generation Sequencing
  • Polymerase Chain Reaction

Cancer Microbiome Sequencing Market, By application:

  • Translational Research
  • Clinical Diagnostics

Cancer Microbiome Sequencing Market, By End User:

  • Biotechnology & Pharmaceutical Companies,
  • Academic & Research Institutions
  • Hospitals & Clinics
  • Others

Cancer Microbiome Sequencing Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Cancer Microbiome Sequencing Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Cancer Microbiome Sequencing Market

5. Voice of Customer

6. Global Cancer Microbiome Sequencing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Component (Kits & Assays, Software, Services)
    • 6.2.2. By Technology (Next Generation Sequencing v/s Polymerase Chain Reaction)
    • 6.2.3. By Application (Translational Research v/s Clinical Diagnostics)
    • 6.2.4. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Hospitals & Clinics, Others)
    • 6.2.5. By Company (2021)
    • 6.2.6. By Region
  • 6.3. Market Map

7. North America Cancer Microbiome Sequencing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Component
    • 7.2.2. By Technology
    • 7.2.3. By Application
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Cancer Microbiome Sequencing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Component
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End User
    • 7.3.2. Canada Cancer Microbiome Sequencing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Component
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End User
    • 7.3.3. Mexico Cancer Microbiome Sequencing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Component
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End User

8. Europe Cancer Microbiome Sequencing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Component
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Cancer Microbiome Sequencing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Component
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End User
    • 8.3.2. Germany Cancer Microbiome Sequencing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Component
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End User
    • 8.3.3. United Kingdom Cancer Microbiome Sequencing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Component
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End User
    • 8.3.4. Italy Cancer Microbiome Sequencing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Component
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Spain Cancer Microbiome Sequencing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Component
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End User

9. Asia-Pacific Cancer Microbiome Sequencing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Component
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Cancer Microbiome Sequencing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Component
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End User
    • 9.3.2. India Cancer Microbiome Sequencing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Component
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End User
    • 9.3.3. Japan Cancer Microbiome Sequencing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Component
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End User
    • 9.3.4. South Korea Cancer Microbiome Sequencing Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Component
        • 9.3.4.2.2. By Technology
        • 9.3.4.2.3. By Application
        • 9.3.4.2.4. By End User
    • 9.3.5. Australia Cancer Microbiome Sequencing Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Component
        • 9.3.5.2.2. By Technology
        • 9.3.5.2.3. By Application
        • 9.3.5.2.4. By End User

10. South America Cancer Microbiome Sequencing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Component
    • 10.2.2. By Technology
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cancer Microbiome Sequencing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Component
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Argentina Cancer Microbiome Sequencing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Component
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End User
    • 10.3.3. Colombia Cancer Microbiome Sequencing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Component
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End User

11. Middle East and Africa Cancer Microbiome Sequencing Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Component
    • 11.2.2. By Technology
    • 11.2.3. By Application
    • 11.2.4. By End User
    • 11.2.5. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Cancer Microbiome Sequencing Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Component
        • 11.3.1.2.2. By Technology
        • 11.3.1.2.3. By Application
        • 11.3.1.2.4. By End User
    • 11.3.2. Saudi Arabia Cancer Microbiome Sequencing Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Component
        • 11.3.2.2.2. By Technology
        • 11.3.2.2.3. By Application
        • 11.3.2.2.4. By End User
    • 11.3.3. UAE Cancer Microbiome Sequencing Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Component
        • 11.3.3.2.2. By Technology
        • 11.3.3.2.3. By Application
        • 11.3.3.2.4. By End User
    • 11.3.4. Turkey Cancer Microbiome Sequencing Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Component
        • 11.3.4.2.2. By Technology
        • 11.3.4.2.3. By Application
        • 11.3.4.2.4. By End User
    • 11.3.5. Egypt Cancer Microbiome Sequencing Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Component
        • 11.3.5.2.2. By Technology
        • 11.3.5.2.3. By Application
        • 11.3.5.2.4. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Illumina, Inc.
  • 14.2. Eurofins Scientific SE
  • 14.3. QIAGEN NV
  • 14.4. Thermo Fischer Scientific, Inc.
  • 14.5. Oxford Nanopore Technologies plc.
  • 14.6. OraSure Technologies, Inc.
  • 14.7. Pacific Biosciences of California, Inc.
  • 14.8. Psomagen, Inc
  • 14.9. Prescient Medicine Holdings, Inc.
  • 14.10. Micronoma Inc.

15. Strategic Recommendations